Personalis Reports Fourth Quarter and Full Year 2019 Financial Results
Fourth Quarter and Full Year 2019 Highlights
- Reported record revenues of
$18.2 million in the fourth quarter and$65.2 million for the full year of 2019, representing a 38% and 73% increase versus$13.2 million in the fourth quarter and$37.8 million for the full year 2018
- A total of 19 different customers placed orders for NeXT during 2019, with 9 of those customers placing their orders in the fourth quarter of 2019
- Launched NeXT Dx Test, a diagnostic test for biopharmaceutical customers to utilize in clinical trials
“We are encouraged by the customer adoption and ramp of new orders for our NeXT platform, with orders exceeding revenues once again this quarter,” said
Fourth Quarter 2019 Financial Results
Revenues were
Gross margin was 36.2% for the three months ended
Operating expenses were
Net loss was
Cash, cash equivalents, and short-term investments were
Full Year 2019 Financial Results
Revenues were
Gross margin was 33.9% for the year ended
Operating expenses were
Net loss was
Outlook and COVID-19
Due to uncertainty surrounding the COVID-19 pandemic,
Webcast and Conference Call Information
About
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from the results predicted, and reported results should not be considered as an indication of future performance. Forward-looking statements include all statements that are not historical facts and can be identified by terms such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “hope,” “intend,” “may,” “might,” “objective,” “ongoing,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would” or similar expressions and the negatives of those terms. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These risks, uncertainties and other factors relate to, among others: the timing and pace of new orders from customers; whether orders for the NeXT platform and revenues from biopharmaceutical customers will increase; the timing of tissue sample receipts from customers, which can materially impact revenue quarter over quarter and year over year; the evolution of cancer therapies and market adoption of our services; our expectations regarding future performance, including 2020 revenues; and the COVID-19 pandemic, which may significantly impact our business and operations, the business and operations of our customers, our ability to access capital and the value of our common stock. In addition, other potential risks and uncertainties that could cause actual results to differ from the results predicted include, among others, those risks and uncertainties included under the captions “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Annual Report on Form 10-K for the year ended
|
||||||||||||||||
CONSOLIDATED STATEMENTS OF OPERATIONS |
||||||||||||||||
(in thousands, except share and per share data) |
||||||||||||||||
|
|
Three Months Ended |
|
Year Ended |
||||||||||||
|
|
2019 |
|
2018 |
|
2019 |
|
2018 |
||||||||
|
|
(unaudited) |
|
|
|
|
|
|
|
|
||||||
Revenues |
|
$ |
18,154 |
|
|
$ |
13,157 |
|
|
$ |
65,207 |
|
|
$ |
37,774 |
|
Costs and expenses |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Costs of revenues |
|
|
11,589 |
|
|
|
8,328 |
|
|
|
43,127 |
|
|
|
25,969 |
|
Research and development |
|
|
7,373 |
|
|
|
4,281 |
|
|
|
22,418 |
|
|
|
14,304 |
|
Selling, general and administrative |
|
|
6,388 |
|
|
|
3,696 |
|
|
|
22,080 |
|
|
|
11,271 |
|
Total costs and expenses |
|
|
25,350 |
|
|
|
16,305 |
|
|
|
87,625 |
|
|
|
51,544 |
|
Loss from operations |
|
|
(7,196 |
) |
|
|
(3,148 |
) |
|
|
(22,418 |
) |
|
|
(13,770 |
) |
Interest income |
|
|
580 |
|
|
|
78 |
|
|
|
1,620 |
|
|
|
293 |
|
Interest expense |
|
|
— |
|
|
|
(244 |
) |
|
|
(1,133 |
) |
|
|
(1,894 |
) |
Loss on debt extinguishment |
|
|
— |
|
|
|
— |
|
|
|
(1,704 |
) |
|
|
(4,658 |
) |
Other (expense) income, net |
|
|
(25 |
) |
|
|
(239 |
) |
|
|
(1,440 |
) |
|
|
150 |
|
Loss before income taxes |
|
|
(6,641 |
) |
|
|
(3,553 |
) |
|
|
(25,075 |
) |
|
|
(19,879 |
) |
Provision for income taxes |
|
|
(4 |
) |
|
|
(2 |
) |
|
|
(9 |
) |
|
|
(7 |
) |
Net loss |
|
$ |
(6,645 |
) |
|
$ |
(3,555 |
) |
|
$ |
(25,084 |
) |
|
$ |
(19,886 |
) |
Net loss per share, basic and diluted |
|
$ |
(0.21 |
) |
|
$ |
(1.16 |
) |
|
$ |
(1.39 |
) |
|
$ |
(6.49 |
) |
Weighted-average shares outstanding, basic and diluted |
31,205,546 |
3,066,365 |
18,011,470 |
3,063,157 |
|
||||||||||||||||
SUPPLEMENTAL REVENUE INFORMATION |
||||||||||||||||
(in thousands) |
||||||||||||||||
|
|
Three Months Ended |
|
Year Ended |
||||||||||||
|
|
2019 |
|
2018 |
|
2019 |
|
2018 |
||||||||
|
|
(unaudited) |
|
|
|
|
|
|
|
|
||||||
VA MVP |
|
$ |
13,754 |
|
|
$ |
6,129 |
|
|
$ |
43,545 |
|
|
$ |
18,601 |
|
All other customers |
|
|
4,400 |
|
|
|
7,028 |
|
|
|
21,662 |
|
|
|
19,173 |
|
Total |
|
$ |
18,154 |
|
|
$ |
13,157 |
|
|
$ |
65,207 |
|
|
$ |
37,774 |
|
|
||||||||
CONSOLIDATED BALANCE SHEETS |
||||||||
(in thousands, except share and per share data) |
||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
|
2019 |
|
2018 |
||||
Assets |
|
|
|
|
|
|
|
|
Current assets |
|
|
|
|
|
|
|
|
Cash and cash equivalents |
|
$ |
55,046 |
|
|
$ |
19,744 |
|
Short-term investments |
|
|
73,243 |
|
|
|
— |
|
Accounts receivable, net |
|
|
3,300 |
|
|
|
4,457 |
|
Inventory and other deferred costs |
|
|
4,606 |
|
|
|
3,432 |
|
Prepaid expenses and other current assets |
|
|
3,383 |
|
|
|
1,926 |
|
Total current assets |
|
|
139,578 |
|
|
|
29,559 |
|
Property and equipment, net |
|
|
14,106 |
|
|
|
11,452 |
|
Operating lease right-of-use assets |
|
|
1,845 |
|
|
|
— |
|
Other long-term assets |
|
|
1,762 |
|
|
|
659 |
|
Total assets |
|
$ |
157,291 |
|
|
$ |
41,670 |
|
Liabilities, Redeemable Convertible Preferred Stock, and Stockholders’ Equity (Deficit) |
|
|
|
|
|
|
|
|
Current liabilities |
|
|
|
|
|
|
|
|
Accounts payable |
|
$ |
7,337 |
|
|
$ |
6,565 |
|
Accrued and other current liabilities |
|
|
6,648 |
|
|
|
3,392 |
|
Contract liabilities |
|
|
35,977 |
|
|
|
42,897 |
|
Short-term debt |
|
|
— |
|
|
|
4,996 |
|
Total current liabilities |
|
|
49,962 |
|
|
|
57,850 |
|
Redeemable convertible preferred stock warrant liability |
|
|
— |
|
|
|
683 |
|
Other long-term liabilities |
|
|
639 |
|
|
|
121 |
|
Total liabilities |
|
|
50,601 |
|
|
|
58,654 |
|
Commitments and Contingencies |
|
|
|
|
|
|
|
|
Redeemable convertible preferred stock |
|
|
— |
|
|
|
89,404 |
|
Stockholders’ equity (deficit) |
|
|
|
|
|
|
|
|
Common stock, |
|
|
3 |
|
|
|
1 |
|
Additional paid-in capital |
|
|
247,282 |
|
|
|
9,131 |
|
Accumulated other comprehensive loss |
|
|
(6 |
) |
|
|
(15 |
) |
Accumulated deficit |
|
|
(140,589 |
) |
|
|
(115,505 |
) |
Total stockholders’ equity (deficit) |
|
|
106,690 |
|
|
|
(106,388 |
) |
Total liabilities, redeemable convertible preferred stock, and stockholders’ equity (deficit) |
|
$ |
157,291 |
|
|
$ |
41,670 |
|
View source version on businesswire.com: https://www.businesswire.com/news/home/20200325005154/en/
Investor Relations Contact:
investors@personalis.com
415-202-5678
Media Contact:
pr@personalis.com
www.personalis.com
650-752-1300
Source: